| Literature DB >> 34827691 |
Nasser M Al-Daghri1, Saba Abdi1, Shaun Sabico1, Abdullah M Alnaami1, Kaiser A Wani1, Mohammed G A Ansari1, Malak Nawaz Khan Khattak1, Nasiruddin Khan2, Gyanendra Tripathi3, George P Chrousos4, Philip G McTernan5.
Abstract
Premature aging, as denoted by a reduced telomere length (TL), has been observed in several chronic inflammatory diseases, such as obesity and type 2 diabetes mellitus (T2DM). However, no study to date has addressed the potential inflammatory influence of the gut-derived Gram-negative bacterial fragments lipopolysaccharide, also referred to as endotoxin, and its influence on TL in low-grade inflammatory states such as type 2 diabetes mellitus (T2DM). The current study therefore investigated the influence of endotoxin and inflammatory factors on telomere length (TL) in adults with (T2DM: n = 387) and without (non-diabetic (ND) controls: n = 417) obesity and T2DM. Anthropometric characteristics were taken, and fasted blood samples were used to measure biomarkers, TL, and endotoxin. The findings from this study highlighted across all participants that circulating endotoxin (r = -0.17, p = 0.01) was inversely associated with TL, noting that endotoxin and triglycerides predicted 18% of the variance perceived in TL (p < 0.001). Further stratification of the participants according to T2DM status and sex highlighted that endotoxin significantly predicted 19% of the variance denoted in TL among male T2DM participants (p = 0.007), where TL was notably influenced. The influence on TL was not observed to be impacted by anti-T2DM medications, statins, or anti-hypertensive therapies. Taken together, these results show that TL attrition was inversely associated with circulating endotoxin levels independent of the presence of T2DM and other cardiometabolic factors, suggesting that low-grade chronic inflammation may trigger premature biological aging. The findings further highlight the clinical relevance of mitigating the levels of circulating endotoxin (e.g., manipulation of gut microbiome) not only for the prevention of chronic diseases but also to promote healthy aging.Entities:
Keywords: endotoxin; inflammation; telomere length; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2021 PMID: 34827691 PMCID: PMC8615790 DOI: 10.3390/biom11111693
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Clinical characteristics of participants.
| Parameters | All | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ND Control | T2DM | ND Control | T2DM | ND Control | T2DM | ||||
| N | 417 | 387 | 183 | 202 | 234 | 185 | |||
| Obese (%) | 207 (54.5) | 195 (52.4) | 0.85 | 67 (39.4) | 73 (36.1) | 0.57 | 140 (66.7) | 122 (67.8) | 0.47 |
| Hypertensive (%) | 129 (30.9) | 165 (42.6) | 0.001 | 53 (29.0) | 77 (38.1) | 0.07 | 76 (32.5) | 88 (47.6) | 0.002 |
| Insulin Analogs (%) | - | 85 (10.6) | - | 48 (12.5) | - | 37 (8.8) | |||
| Metformin (%) | - | 23 (2.9) | - | 14 (3.6) | - | 9 (2.1) | |||
| Statins (%) | - | 17 (2.1) | - | 13 (3.4) | - | 4 (1.0) | |||
| Antihypertensive (%) | 11 (2.6) | 31 (8.0) | <0.001 | 5 (2.7) | 16 (7.9) | <0.001 | 6 (2.6) | 15 (8.1) | <0.001 |
| Aspirin (%) | 4 (0.2) | 32 (8.3) | <0.001 | 3 (1.5) | 23 (12.6) | <0.001 | 1 (0.4) | 9 (4.9) | <0.001 |
Note: Data presented as N (%). Significant at p < 0.05.
Anthropometrics and lipid profile of participants.
| Parameters | All | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ND Control | T2DM | ND Control | T2DM | ND Control | T2DM | ||||
| N | 417 | 387 | 183 | 202 | 234 | 185 | |||
| Age (years) | 55.7 ± 7.4 | 58.7 ± 8.1 | <0.001 | 55.9 ± 8.4 | 60.9 ± 8.4 | <0.001 | 55.5 ± 6.5 | 56.3 ± 6.9 | 0.26 |
| BMI (kg/m2) | 30.9 ± 5.6 | 30.6 ± 5.4 | 0.52 | 28.5 ± 4.7 | 29.1 ± 4.8 | 0.27 | 32.8 ± 5.5 | 32.3 ± 5.5 | 0.36 |
| WHR | 0.94 ± 0.1 | 0.96 ± 0.1 | <0.001 | 0.96 ± 0.07 | 1.0 ± 0.06 | <0.001 | 0.91 ± 0.09 | 0.91 ± 0.07 | 0.96 |
| SBP (mmHg) | 125.1 ± 14.3 | 132.4 ± 14.5 | <0.001 | 125.9 ± 13.9 | 132.3 ± 12.9 | <0.001 | 124.5 ± 14.5 | 132.4 ± 15.9 | <0.001 |
| DBP (mmHg) | 77.9 ± 9.6 | 80.2 ± 8.7 | 0.001 | 79.8 ± 7.8 | 81.2 ± 6.0 | 0.09 | 76.4 ± 10.5 | 79.3 ± 10.6 | 0.007 |
| Total Cholesterol | 5.04 ± 1.1 | 5.07 ± 1.2 | 0.64 | 5.1 ± 1.2 | 4.9 ± 1.1 | 0.28 | 4.9 ± 0.9 | 5.2 ± 1.2 | 0.06 |
| HDL Cholesterol | 1.0 ± 0.3 | 0.99 ± 0.3 | 0.88 | 0.84 ± 0.3 | 0.92 ± 0.3 | 0.004 | 1.1 ± 0.3 | 1.1 ± 0.2 | 0.18 |
| LDL Cholesterol | 3.2 ± 0.9 | 3.1 ± 0.9 | 0.46 | 3.4 ± 1.0 | 3.1 ± 0.9 | 0.02 | 3.1 ± 0.8 | 3.2 ± 0.9 | 0.22 |
| LDL/HDL ratio | 3.7 ± 2.5 | 3.5 ± 1.5 | 0.13 | 4.4 ± 2.1 | 3.7 ± 1.6 | <0.001 | 3.2 ± 2.6 | 3.2 ± 1.3 | 0.86 |
| Triglycerides # | 1.5 (1.2–2.1) | 1.7 (1.3–2.3) | 0.002 | 1.7 (1.3–2.3) | 1.7 (1.2–2.3) | 0.61 | 1.4 (1.1–2.0) | 1.7 (1.3–2.4) | <0.001 |
Note: Data presented as mean ± SD, median (1st–3rd) percentile, and mean (95%CI), median (25th–75th) percentile change for Gaussian and non-Gaussian variables; # denotes non-Gaussian variable, presented as median. ND, non-diabetic; BMI, body mass index; WHR, waist–hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Significant at p < 0.01.
Telomere length, glycemic profile, and pro-inflammatory markers in participants with or without T2DM.
| Parameters | All | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ND Control | T2DM | ND Control | T2DM | ND Control | T2DM | ||||
| N | 417 | 387 | 234 | 185 | 183 | 202 | |||
| TL (BP) | 5880 ± 1464 | 5554 ± 1346 | <0.001 | 5830 ± 1705 | 5435 ± 1380 | 0.02 | 5912.3 ± 1290 | 5686 ± 199 | 0.08 |
| Glucose (mmol/L) | 5.7 ± 0.9 | 10.2 ± 3.1 | <0.001 | 5.8 ± 0.9 | 10.0 ± 3.0 | <0.001 | 5.6 ± 0.8 | 10.3 ± 3.2 | <0.001 |
| Insulin (μU/mL) | 11.1 (6.9–16.3) | 10.1 (6.5–16.1) | 0.14 | 10.3 (6.8–16.8) | 9.7 (6.3–16.0) | 0.812 | 11.8 (7.2–16.3) | 10.4 (6.5–16.1) | 0.087 |
| HOMA-IR | 2.8 (1.7–4.5) | 4.2 (2.7–7.6) | <0.001 | 2.5 (1.5–4.6) | 3.9 (2.7–7.6) | <0.001 | 2.9 (1.9–4.4) | 4.3 (2.7–7.4) | <0.001 |
| Endotoxin (IU/mL) | 3.0 (1.8–4.8) | 2.5 (1.7–4.1) | 0.03 | 2.6 (1.7–4.1) | 2.5 (1.7–4.6) | 0.56 | 3.2 (1.8–4.9) | 2.4 (1.8–3.8) | 0.03 |
| Adiponectin (ug/mL) | 13.5 (5.4–24.9) | 13.9 (8.5–20.2) | 0.38 | 3.4 (1.0–13.1) | 11.8 (8–17) | <0.001 | 18.6 (11.9–34) | 15.8 (10.1–25) | 0.002 |
| Resistin (ng/mL) | 27.3 (2.7–114) | 28.4 (20–41) | 0.97 | 2.2 (1.2–10.1) | 25.7 (18.2–38) | <0.001 | 96.9 (31.4–168) | 30.9 (21.2–43) | <0.001 |
| PAI-1 (ng/mL) | 6.9 (0.3–10.4) | 10.1 (7.4–12.7) | <0.001 | 0.3 (0.1–4.4) | 10.1 (7.4–17) | <0.001 | 9.4 (6.8–12.4) | 10.0 (7.6–12.7) | 0.048 |
| Leptin (ng/mL) | 16.6 (6.4–32.2) | 14.7 (8.3–26.4) | 0.56 | 10.7 (4.7–23.8) | 10.8 (6.2–16.7) | 0.95 | 22.3 (10.5–37) | 20.9 (12.4–33) | 0.99 |
| ANG-II (pg/mL) | 0.9 (0.4–1.2) | 0.2 (0.1–0.4) | <0.001 | 1.0 (0.6–1.3) | 0.2 (0.1–0.5) | <0.001 | 0.20 (0.08–0.3) | 0.21 (0.1–0.4) | 0.18 |
| TNF-α (pg/mL) | 2.4 (1.3–6.1) | 1.3 (0.9–2.1) | <0.001 | 3.7 (1.5–7.2) | 1.3 (0.9–1.9) | <0.001 | 2.0 (1.3–3.4) | 1.4 (0.9–2.1) | <0.001 |
| CRP (ug/mL) | 2.0 (0.8–4.5) | 2.9 (0.9–6.0) | 0.06 | 2.8 (0.9–6.5) | 3.0 (1.5–6.0) | 0.55 | 1.5 (0.7–2.5) | 2.8 (0.2–5.6) | 0.02 |
Note: Data presented as mean ± SD, median (1st–3rd) percentile, and mean (95%CI), median (25th–75th) percentile change for Gaussian and non-Gaussian variables. ND, non-diabetic; TL, telomere length; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; PAI-1, plasminogen activator inhibitor-1; ANG-II, angiotensin II; TNF-α, tumor necrosis factor α; CRP, C-reactive protein. P-values are obtained from independent sample t-test and Mann–Whitney U test for Gaussian and non-Gaussian variables, respectively. p-value < 0.05 considered significant.
Significant associations of TL with measured parameters.
| Parameters | All | All | Males | Females | |||
|---|---|---|---|---|---|---|---|
| ND Control | T2DM | ND Control | T2DM | ND Control | T2DM | ||
| N (M/F) | 804 | 417 (183/234) | 387 (202/185) | 183 | 202 | 234 | 185 |
| Age (years) | 0.24 ** | ||||||
| WHR | −0.16 * | ||||||
| Glucose (mmol/L) | 0.20 ** | 0.24 ** | |||||
| Total Cholesterol | −0.08 * | −0.10 * | |||||
| HDL Cholesterol | −0.08 * | ||||||
| LDL/HDL ratio | −0.13 * | ||||||
| Triglycerides # | 0.15 * | ||||||
| HOMA-IR | 0.14 * | 0.20 * | |||||
| Endotoxin (IU/mL) | −0.17 ** | −0.27 ** | −0.18 ** | −0.24 ** | −0.29 ** | ||
| Adiponectin (ug/mL) | 0.18 * | 0.23 * | |||||
| Resistin (ng/mL) | 0.15 * | 0.20 * | |||||
| PAI-1 (ng/mL) | 0.18 * | 0.25 ** | 0.32** | 0.27 ** | 0.25 * | ||
| TNF-α (pg/mL) | −0.15 * | ||||||
| CRP (ug/mL) | −0.14 * | −0.15 * | −0.25 ** | ||||
Note: Data presented as coefficient (R); # denotes not normal; * denotes significance at 0.05 level; ** denotes significance at 0.01 level. Parameters not included in the table denote no significant correlations in all groups.
Significant predictors of TL and endotoxin.
| Parameters | N | Significant Predictors of TL |
|---|---|---|
| All Participants | 804 | Endotoxin, Triglycerides, BMI |
| T2DM | 387 | Endotoxin, Glucose |
| ND Control | 417 | Glucose, BMI |
| Male T2DM | 185 | Endotoxin |
| Male ND Control | 235 | BMI and Glucose |
| Female T2DM | 202 | HbA1c |
| Female ND Control | 183 | Glucose |
Note: Data presented as adjusted R2. Independent variables: age, BMI, WHR, glucose, triglycerides, adiponectin, resistin, leptin, PAI-1, TNF-α, insulin, 25(OH)D, ANGII, CRP, TL, and endotoxin.
Figure 1Differences in endotoxin levels according to anti-T2DM medications.